PYPD
PolyPid Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$4.88
+3.39%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +8.9%
- EBIT
- +103.6%
- EPS
- +61.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +13.6%
- EPS
- +19.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -24.0%
- EBIT
- -17.6%
- Net income
- -17.7%
- EPS
- +57.4%
- Free cash flow
- +100.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026